RU2418797C2 - Лиганды никотинового рецептора альфа-7, их получение и применение - Google Patents

Лиганды никотинового рецептора альфа-7, их получение и применение Download PDF

Info

Publication number
RU2418797C2
RU2418797C2 RU2007128062/04A RU2007128062A RU2418797C2 RU 2418797 C2 RU2418797 C2 RU 2418797C2 RU 2007128062/04 A RU2007128062/04 A RU 2007128062/04A RU 2007128062 A RU2007128062 A RU 2007128062A RU 2418797 C2 RU2418797 C2 RU 2418797C2
Authority
RU
Russia
Prior art keywords
azabicyclo
oct
indazole
carboxylic acid
ester
Prior art date
Application number
RU2007128062/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2007128062A (ru
Inventor
Трук Мин НГУЙЕН (US)
Трук Мин НГУЙЕН
Вэньге СЕ (US)
Вэньге СЕ
Ричард ШУМАХЕР (US)
Ричард Шумахер
Брайан ХЕРБЕРТ (US)
Брайан Херберт
Ашок ТЕХИМ (US)
Ашок Техим
Original Assignee
Мемори Фармасьютиклз Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мемори Фармасьютиклз Корпорейшн filed Critical Мемори Фармасьютиклз Корпорейшн
Publication of RU2007128062A publication Critical patent/RU2007128062A/ru
Application granted granted Critical
Publication of RU2418797C2 publication Critical patent/RU2418797C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2007128062/04A 2004-12-22 2005-12-21 Лиганды никотинового рецептора альфа-7, их получение и применение RU2418797C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63777104P 2004-12-22 2004-12-22
US60/637,771 2004-12-22

Publications (2)

Publication Number Publication Date
RU2007128062A RU2007128062A (ru) 2009-01-27
RU2418797C2 true RU2418797C2 (ru) 2011-05-20

Family

ID=36177987

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007128062/04A RU2418797C2 (ru) 2004-12-22 2005-12-21 Лиганды никотинового рецептора альфа-7, их получение и применение

Country Status (15)

Country Link
US (2) US7625924B2 (enExample)
EP (1) EP1828179B1 (enExample)
JP (1) JP2008525464A (enExample)
KR (1) KR20070087674A (enExample)
CN (1) CN101124224A (enExample)
AT (1) ATE455776T1 (enExample)
AU (1) AU2005319248A1 (enExample)
BR (1) BRPI0517494A (enExample)
CA (1) CA2591817A1 (enExample)
DE (1) DE602005019094D1 (enExample)
ES (1) ES2342675T3 (enExample)
MX (1) MX2007007328A (enExample)
PL (1) PL1828179T3 (enExample)
RU (1) RU2418797C2 (enExample)
WO (1) WO2006069097A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580329C (en) 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
EP1977746B8 (en) * 2007-04-02 2014-09-24 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009046025A1 (en) * 2007-10-01 2009-04-09 Comentis, Inc. Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease
CA2728451C (en) * 2008-08-12 2013-09-24 F. Hoffmann-La Roche Ag Salicylamide derivatives as nicotinic alpha 7 modulators
CA2740311C (en) * 2008-10-13 2013-09-17 F. Hoffmann-La Roche Ag Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
US20110172428A1 (en) 2010-01-12 2011-07-14 Shan-Ming Kuang Methods for the preparation of indazole-3-carboxylic acid and n-(s)-1-azabicyclo[2.2.2]oct-3-yl-1h-indazole-3-carboxamide hydrochloride salt
JP2013523092A (ja) 2010-03-26 2013-06-17 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 非喫煙用タバコ製品の消費中の感覚刺激の抑制
US8952038B2 (en) 2010-03-26 2015-02-10 Philip Morris Usa Inc. Inhibition of undesired sensory effects by the compound camphor
US9233109B2 (en) 2010-04-23 2016-01-12 University Of Florida Research Foundation, Inc. Compositions, methods of use, and methods of treatment
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8242276B2 (en) 2010-06-30 2012-08-14 Hoffmann-La Roche Inc. Methods for the preparation of N-(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide hydrochloride salt
KR101928505B1 (ko) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
WO2013116413A1 (en) * 2012-02-02 2013-08-08 Targacept, Inc. Diazabicyclo[3.3.1]nonanes, methods of synthesis, and uses thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP3166940A4 (en) 2014-07-11 2018-04-25 Alpharmagen, LLC Quinuclidine compounds for modulating alpha7 -nicotinic acetylcholine receptor activity
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
WO2016145373A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
JP2018516973A (ja) * 2015-06-10 2018-06-28 フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． α７−ニコチン性アセチルコリン受容体のアゴニストとしてのアミノベンゾイソオキサゾール化合物
EP3334740A4 (en) 2015-08-12 2019-02-06 Axovant Sciences GmbH GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
EA202190718A1 (ru) 2018-09-13 2021-07-01 Бристол-Маерс Сквибб Компани Индазолкарбоксамиды в качестве ингибиторов киназ
US12084426B2 (en) 2018-09-13 2024-09-10 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
CN111808907B (zh) * 2019-10-09 2021-07-09 北京原基华毅生物科技有限公司 调整觉醒的物质及方法
TW202412782A (zh) * 2022-05-25 2024-04-01 天主教魯汶大學 用於治療ｔｒｐｍ３介導之病症的吲唑衍生物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2143432C1 (ru) * 1994-12-28 1999-12-27 Яманоути Фармасьютикал Ко., Лтд. Новые производные хинуклидина и медицинские композиции, содержащие их
WO2004029050A1 (en) * 2002-09-25 2004-04-08 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59004A0 (en) 1978-12-30 1980-03-31 Beecham Group Ltd Substituted benzamides their preparation and pharmaceutical compositions containing them
FI74707C (fi) 1982-06-29 1988-03-10 Sandoz Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror.
JPS5936675A (ja) 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
FR2548666A1 (fr) 1983-07-08 1985-01-11 Delalande Sa Nouveaux derives du nor-tropane et du granatane, leur procede de preparation et leur application en therapeutique
DE3429830A1 (de) 1983-08-26 1985-03-07 Sandoz-Patent-GmbH, 7850 Lörrach Automatische carbonsaeure- und sulfonsaeureester oder -amide
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8623142D0 (en) 1986-09-26 1986-10-29 Beecham Group Plc Compounds
EP0200444B1 (en) 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
GB8518658D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
US5204356A (en) 1985-07-24 1993-04-20 Glaxo Group Limited Treatment of anxiety
GB8520616D0 (en) 1985-08-16 1985-09-25 Beecham Group Plc Compounds
IN166416B (enExample) 1985-09-18 1990-05-05 Pfizer
GB8525844D0 (en) * 1985-10-19 1985-11-20 Beecham Group Plc Compounds
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
HU202108B (en) 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
GB8701022D0 (en) 1987-01-19 1987-02-18 Beecham Group Plc Treatment
DE3872872T2 (de) 1987-11-14 1993-02-04 Beecham Group Plc 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.
US4950759A (en) 1988-07-07 1990-08-21 Duphar International Research B.V. Substituted 1,7-annelated 1H-indazoles
US4895943A (en) 1988-10-25 1990-01-23 Pfizer Inc. Preparation of 1,4-diazabicyclo(3.2.2)nonane
US5223625A (en) 1988-12-22 1993-06-29 Duphar International Research B.V. Annelated indolo [3,2,-C]lactams
EP0377238A1 (en) 1988-12-22 1990-07-11 Duphar International Research B.V New annelated indolo (3,2-c)-lactams
WO1990014347A1 (fr) 1989-05-24 1990-11-29 Nippon Shinyaku Co., Ltd. Derives d'indole et medicament
FI922124A0 (fi) * 1989-11-17 1992-05-11 Pfizer Azabicykloamider och -estrar som 5-ht3-receptorantagonister.
US5446050A (en) 1989-11-17 1995-08-29 Pfizer Inc. Azabicyclo amides and esters as 5-HT3 receptor antagonists
GB8928837D0 (en) 1989-12-21 1990-02-28 Beecham Group Plc Pharmaceuticals
US5098889A (en) 1990-09-17 1992-03-24 E. R. Squibb & Sons, Inc. Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
US5192770A (en) 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
WO1992012149A1 (en) 1991-01-09 1992-07-23 Smithkline Beecham Plc Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
US5137895A (en) * 1991-04-29 1992-08-11 A. H. Robins Company, Incorporated 3-[N-aroyl(or thioaroyl)aminomethyl]-3-quinuclidinols
GB9121835D0 (en) 1991-10-15 1991-11-27 Smithkline Beecham Plc Pharmaceuticals
US5273972A (en) 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
US5679673A (en) 1992-09-24 1997-10-21 The United States Of America, Represented By The Department Of Health And Human Services Aralkyl bridged diazabicycloalkane derivatives for CNS disorders
IT1256623B (it) 1992-12-04 1995-12-12 Federico Arcamone Antagonisti delle tachichinine, procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche
GB9406857D0 (en) 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US6624173B1 (en) 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
FR2769915B1 (fr) * 1997-10-21 2000-10-13 Synthelabo Derives d'indazole tricycliques, leur preparation et leur application en therapeutique
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
US6653304B2 (en) 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
US6852721B2 (en) 2000-05-25 2005-02-08 Targacept, Inc. Pharmaceutical compositions and methods for use
FR2809732B1 (fr) 2000-05-31 2002-07-19 Sanofi Synthelabo DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE
JP4616971B2 (ja) 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
WO2002036114A1 (en) 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
DE60216830T2 (de) 2001-02-06 2007-06-14 Pfizer Products Inc., Groton Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
US20040147505A1 (en) 2001-06-01 2004-07-29 Dan Peters Novel heteroaryl-diazabicyclo alkanes as cns-modulators
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
AR036041A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
WO2003022856A1 (en) 2001-09-12 2003-03-20 Pharmacia & Upjohn Company Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
US6911543B2 (en) 2001-10-02 2005-06-28 Pfizer Inc. Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
CA2464194A1 (en) 2001-10-26 2003-05-08 Pharmacia & Upjohn Company N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
JP2005510523A (ja) 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
DE10162375A1 (de) 2001-12-19 2003-07-10 Bayer Ag Bicyclische N-Aryl-amide
DE10305922A1 (de) 2002-06-10 2004-03-04 Bayer Ag 2-Heteroarylcarbonsäureamide
AU2003217275A1 (en) 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Azabicyclic compounds for the treatment of disease
WO2003072578A1 (en) 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
ES2197001B1 (es) 2002-03-26 2004-11-16 Laboratorios Vita, S.A. Procedimiento de obtencion de un compuesto farmaceuticamente activo.
CA2480378A1 (en) 2002-05-07 2003-11-20 Neurosearch A/S Novel azacyclic ethynyl derivatives
CN1656093A (zh) 2002-05-30 2005-08-17 神经研究公司 3－取代的奎宁环及其用途
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
EP1546156A1 (en) 2002-08-10 2005-06-29 Astex Technology Limited 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors
PL375533A1 (en) * 2002-08-14 2005-11-28 Neurosearch A/S Novel quinuclidine derivatives and their use
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
FR2845388B1 (fr) 2002-10-08 2004-11-12 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
US7456171B2 (en) 2002-10-08 2008-11-25 Sanofi-Aventis 1,4-Diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof
US6945618B2 (en) 2003-06-02 2005-09-20 Accuride International Inc. Drawer slide adjustment mechanism
DE10334724A1 (de) 2003-07-30 2005-02-24 Bayer Healthcare Ag N-Biarylamide
CN103724343A (zh) * 2004-03-25 2014-04-16 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2143432C1 (ru) * 1994-12-28 1999-12-27 Яманоути Фармасьютикал Ко., Лтд. Новые производные хинуклидина и медицинские композиции, содержащие их
WO2004029050A1 (en) * 2002-09-25 2004-04-08 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RYO TATSUMI et al. Bioorganic & Medicinal Chemistry Letters. 14, 2004, 3781-3784. JOHN E. MACOR et al. Bioorganic & Medicinal Chemistry Letters. 11, 2001, 319-321. *

Also Published As

Publication number Publication date
US7625924B2 (en) 2009-12-01
KR20070087674A (ko) 2007-08-28
EP1828179A2 (en) 2007-09-05
ES2342675T3 (es) 2010-07-12
PL1828179T3 (pl) 2010-08-31
MX2007007328A (es) 2007-07-25
US20100016351A1 (en) 2010-01-21
WO2006069097A2 (en) 2006-06-29
BRPI0517494A (pt) 2008-10-14
CN101124224A (zh) 2008-02-13
JP2008525464A (ja) 2008-07-17
US20060167039A1 (en) 2006-07-27
CA2591817A1 (en) 2006-06-29
DE602005019094D1 (de) 2010-03-11
EP1828179B1 (en) 2010-01-20
WO2006069097A3 (en) 2006-10-05
AU2005319248A1 (en) 2006-06-29
ATE455776T1 (de) 2010-02-15
RU2007128062A (ru) 2009-01-27

Similar Documents

Publication Publication Date Title
RU2418797C2 (ru) Лиганды никотинового рецептора альфа-7, их получение и применение
RU2389729C2 (ru) 1н-индазолы, 1, 2-бензизоксазолы и 1, 2-бензизотиазолы, их получение и применение
KR101129933B1 (ko) 인다졸, 벤조티아졸 및 벤조이소티아졸 및 그의 제조 및용도
EP1745046B1 (en) 1 h-indazoles, benzothiazoles, 1,2-benziosoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
US7932248B2 (en) 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
CN101124226A (zh) 1h-吲唑、苯并噻唑、1,2-苯并异噁唑、1,2-苯并异噻唑和色酮以及它们的制备和用途
HK1112743A (en) Nicotinic alpha-7 receptor ligands and preparation and uses thereof
MXPA06007168A (en) Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20121222